Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting

Barlati, Stefano; Nibbio, Gabriele; Bianchi, Francesco; Gigli, Elena Butti Lemmi; Calzavara‐Pinton, Irene; Cerati, Caterina; Fiori, Jacopo; Lisoni, Jacopo; Deste, Giacomo; Vita, Antonio

doi:10.1016/j.psychres.2022.114878

Cited by 6 publications

(6 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, other research yielded different results. An observational study in Italy in a real-world clinical setting found no significant differences between 2020 and 2019 in the total number of patients on LAI treatment and the number of dropouts, although a significant reduction in new LAI starts was observed [ 59 ]. Another retrospective observational study in Canada examined national and provincial patient-level longitudinal prescribing data from pharmacies’ database that corresponded to 72% of national prescriptions.…”

Section: Discussionmentioning

confidence: 99%

Use of Long-Acting Injectable Antipsychotics in a Clinical Sample of Community-Dwelling Patients with Schizophrenia-Spectrum Disorders in Rural Greece

Peritogiannis¹,

Tsoli²,

Gioti³

et al. 2023

JCM

View full text Add to dashboard Cite

Data on the use of long-acting injectable antipsychotics (LAIs) in rural community mental healthcare settings are scarce. This study aimed to investigate the prescription patterns of LAIs in a clinical sample of patients with schizophrenia-spectrum disorders in rural Greece. All patients with schizophrenia-spectrum disorders who regularly attend the Mobile Mental Health Unit of the prefectures of Ioannina and Thesprotia (MMHU I-T) in northwestern Greece were included in the study. The sample consists of 87 patients (59 males and 28 females) with a mean age of 54.4 years and a mean illness duration of 28 years. Most patients (72.4%) received antipsychotic monotherapy, and nearly 30% received an LAI formulation, mostly a second-generation LAI (20 of 26 patients, 76.9%). The treatment regimen comprised benzodiazepines in one-third of the patients and antidepressants in one-quarter. There was no statistically significant association between treatment regimen and the clinical and demographic variables studied, except for biological sex (female). The percentage of patients treated with LAIs in this study was almost three times higher than the rate previously reported in Greece and is higher than the rates reported in other countries. Patients with schizophrenia-spectrum disorders in rural Greece may have adequate access to innovative treatment with second-generation LAIs. Further research is needed to demonstrate the cost-effectiveness of LAI treatment in rural communities and to elucidate the factors associated with such treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Long-Acting Injectable Antipsychotics in a Clinical Sample of Community-Dwelling Patients with Schizophrenia-Spectrum Disorders in Rural Greece

Peritogiannis¹,

Tsoli²,

Gioti³

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…5,6 Recent literature has suggested other factors, such as patient reluctance to leave home and a reduction in the number of injections due to shorter working hours of clinics. 7 Barlati et al 4 reported that the decrease in new LAIs prescriptions in Italian civilian hospitals was related to a switch to oral medications aimed to prevent reduced number of visits during the COVID-19 pandemic and interactions with drugs administered for severe cases.…”

Section: Lais Prescribing Trends Before and After The Covid-19 Pandem...mentioning

confidence: 99%

“…Following the implementation of lockdown measures after the declaration of COVID‐19 as a pandemic by the World Health Organization (WHO) in March 2020, access to several medical facilities was temporarily restricted. Psychiatric facilities also implemented various preventive measures in prescribing LAIs 4 …”

Section: Lais Prescriptions During the Covid‐19 Pandemicmentioning

confidence: 99%

Long‐acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID‐19 pandemic: A micro‐narrative review

Oguchi,

Miyake,

Ando

2024

Neuropsychopharm Rep

View full text Add to dashboard Cite

The coronavirus disease pandemic has presented healthcare systems with unprecedented challenges globally and substantially impacted the management of chronic diseases such as schizophrenia. This narrative review highlights the usefulness of long‐acting injectable antipsychotics (LAIs) as maintenance therapy for patients with schizophrenia during the pandemic. The analysis of relevant literature and psychiatric survey data revealed diverse trends in LAIs prescription and patient adherence with oral antipsychotics. Although some studies have reported a decrease in LAIs prescriptions owing to pandemic‐related disruptions, others have suggested stable patient adherence with oral antipsychotics. Approximately 70% of Japanese psychiatrists reported an increase in schizophrenia relapse rates in a survey, underscoring the critical role of LAIs in maintaining therapeutic stability. The potential benefits of LAIs with extended dosing intervals have been highlighted, including improving oral medication adherence and reducing the frequency of hospital visits. In conclusion, this review emphasizes the continued need for uninterrupted LAIs therapy in conjunction with community and home‐based care despite the disruptions caused by the coronavirus disease pandemic. Further development of LAIs maintenance therapy strategies considering the ongoing pandemic and potential future public health emergencies are required.

show abstract

Section: Key Pointsmentioning

confidence: 99%

“…The prescription of long-acting injectable antipsychotics (LAI) has been a challenge in many countries with various results [44][45][46][47][48][49][50][51][52][53][54][55]. In the United States, Canada, Italy, and Greece, no significant increase of LAI disruption has been identified in electronic records [25,44,45,53]. In Romania, a decrease of 48% of LAI initiation was identified in the 12 months following the COVID-19 onset compared with the 12 months before in a mirror study [46].…”

Section: Key Pointsmentioning

confidence: 99%

Lessons from the coronavirus disease 2019 pandemic in schizophrenia: a review

Fond

Boyer

2023

Current Opinion in Psychiatry

View full text Add to dashboard Cite

Purpose of reviewMultiple countries have reported increased COVID-19 mortality in patients with schizophrenia. The purpose of this review was to synthetize the consequences of the pandemic on patients with schizophrenia including vaccination data.Recent findingsWe have synthetized data on the increased risk of infection and increased mortality, the impact of the pandemic and lockdowns on psychiatric care, vaccination policies, unwillingness to vaccine in patients and the rates of vaccination.SummarySchizophrenia has been confirmed at increased risk of both COVID-19 infection and developing a severe/lethal form of the infection. Patients with schizophrenia should, therefore, be prioritized for vaccination whenever possible and should be prioritized for psychiatric and somatic care access. Psychotic symptomatology may be a barrier to vaccination in some patients, and heterogenous vaccination rates were identified in national databases. The COVID-19 pandemic has been also a unique opportunity to develop telehealth. A mixed face-to-face and distance model should be encouraged, whenever possible, to improve the experience of patients, relatives and healthcare professionals. No major change of long-acting antipsychotics has been reported in most countries, and there was no consistent evidence for clozapine prescription to increase the risk of COVID-19 infection or severe outcomes.

show abstract

Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting

Cited by 6 publications

References 70 publications

Use of Long-Acting Injectable Antipsychotics in a Clinical Sample of Community-Dwelling Patients with Schizophrenia-Spectrum Disorders in Rural Greece

Use of Long-Acting Injectable Antipsychotics in a Clinical Sample of Community-Dwelling Patients with Schizophrenia-Spectrum Disorders in Rural Greece

Long‐acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID‐19 pandemic: A micro‐narrative review

Lessons from the coronavirus disease 2019 pandemic in schizophrenia: a review

Contact Info

Product

Resources

About